EGFR and cancer: This was a single-center retrospective cohort study that aimed to determine whether thromboembolism incidence differs between VEGF and EGFR inhibitors administered to patients with unresectable advanced or recurrent colorectal cancer, and whether molecular-targeted therapies increase thromboembolism incidence compared with the cancer-bearing condition.